Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
20.91
-0.32 (-1.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exelixis Inc
< Previous
1
2
3
4
5
Next >
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
August 16, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
August 05, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
July 22, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
July 08, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
June 18, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
June 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma
June 04, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma
June 04, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
June 04, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
May 26, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
May 24, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
May 04, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
April 27, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
April 22, 2021
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.